#USA #Indianapolis #Healthcare Conference #J.P. Morgan #Eli Lilly

Eli Lilly at the J.P. Morgan Healthcare Conference 2025

Eli Lilly and Company, a key player in the pharmaceutical industry, has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled to take place from January 12 to 15, 2025. This highly anticipated event will feature an array of discussions surrounding the latest advancements in healthcare, with a specific highlight from Lilly's Chair and CEO, David A. Ricks.

Event Details

On January 13, at 5:15 PM Eastern Time, David Ricks will engage in a fireside chat, providing insights into Lilly's innovative approaches and upcoming projects in clinical research and biopharmaceutical development. The conversation is expected to cover the company's ongoing commitment to redefining diabetes care, tackling obesity management, and addressing Alzheimer's disease, alongside a focus on diverse clinical trials.

For those unable to attend, a live audio webcast of the chat will be accessible on Lilly’s investor relations website, allowing a broader audience to connect with the conversation. Additionally, a recording of this presentation will be available for approximately 90 days, ensuring accessibility to valuable insights.

About Eli Lilly

Eli Lilly has been at the forefront of medical innovation for nearly 150 years, striving to transform scientific discoveries into powerful medications that improve lives globally. The company leverages biotechnology, chemistry, and genetic medicine to address some of the world’s most pressing health issues. With a suite of medications that aid millions, Lilly is committed not only to breakthrough science but also to ensuring these innovations are available and affordable for all.

Key areas of focus include:

• - Innovative Diabetes Solutions: Advancements in diabetes care that enhance patient well-being and outcomes.
• - Obesity Treatment: Novel pharmaceutical approaches that combat obesity and its long-term effects.
• - Alzheimer's Disease Research: Pioneering efforts to develop treatments that may alter the trajectory of Alzheimer’s disease.
• - Immune System Disorders: Solutions aimed at managing debilitating disorders affecting the immune system.
• - Cancer Management: Transforming the treatment landscape for difficult-to-treat cancers into manageable conditions.

Commitment to Diversity and Accessibility

Eli Lilly continually emphasizes the importance of diversity in clinical trials, aiming to reflect the patient populations they serve. This commitment is part of a broader strategy to foster inclusivity in medical research, ensuring that all populations have access to groundbreaking treatments.

Through their participation in the J.P. Morgan Healthcare Conference, Lilly underscores its mission to make healthcare advancements accessible to all, contributing to a healthier world. This event also presents an invaluable opportunity for stakeholders across the healthcare sector to engage directly with one of the leaders in pharmaceutical innovation.

For more information about Eli Lilly and its upcoming participation in the J.P. Morgan Healthcare Conference, please visit Lilly’s Official Website. Updates and details about their innovations can also be followed through their social media channels on Facebook, Instagram, and LinkedIn.

The participation of Eli Lilly at such a prestigious platform highlights the invaluable contributions they are making towards improving healthcare outcomes and addressing significant global health challenges. As the healthcare landscape continues to evolve, the insights shared at this conference will likely serve as a beacon for future advancements and collaborations in the industry.